ArticleCureus2026
Endoscopic Transsphenoidal Versus Transcranial Surgery for Sellar and Suprasellar Tumors: Seven-Year Comparative Outcomes in the Philippines.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Sellar and suprasellar tumors constitute a significant proportion of intracranial neoplasms encountered in neurosurgical practice, with pituitary adenomas being the most common. The endoscopic transsphenoidal approach has become increasingly preferred due to its minimally invasive nature and enhanced visualization. However, comparative outcome data between transsphenoidal and transcranial approaches remain limited in low- and middle-income settings. This study aimed to compare clinical outcomes between these two surgical approaches in a tertiary government end-referral medical center in the Philippines. Methods A retrospective review of 129 consecutive adult patients who underwent surgical management between January 2019 and December 2025 was conducted. Patients were divided into endoscopic transsphenoidal (n = 109) and transcranial (n = 20) groups. Demographic data, comorbidities, pathology, tumor size, perioperative mortality, complications, visual improvement, and crude recurrence were analyzed using Chi-square/Fisher's exact tests and Firth's penalized logistic regression. Results Pituitary adenomas predominated (77.5%; non-functioning 69.0%), followed by craniopharyngiomas (11.6%). Mean tumor diameter was 3.4 cm (range 1.8-5.5 cm), with 17.8% classified as giant (≥4.0 cm). Endoscopic transsphenoidal surgery was used in 84.5% of definitive resections (109/129). Perioperative mortality was 2.8% versus 15.0% (Fisher's exact p = 0.047), visual improvement 95.1% versus 75.0% (Fisher's exact p = 0.023), and major complications 6.4% versus 25.0% (Fisher's exact p = 0.058) in the transsphenoidal and transcranial groups, respectively. On Firth's penalized logistic regression (primary analysis due to low events-per-variable ratio of 1.2), a transcranial approach was associated with more than eightfold higher odds of mortality (adjusted OR 8.2, 95% CI 1.4-46.1; p = 0.018), whereas giant tumor size was associated with fourfold higher odds of death (adjusted OR 4.0, 95% CI 1.1-14.8; p = 0.035. Crude recurrence rates were 8.4% for adenomas, 26.7% for craniopharyngiomas, and 14.3% for meningioma/other lesions (10.9% overall). Conclusion The endoscopic transsphenoidal approach was associated with significantly lower perioperative mortality and superior visual outcomes compared to transcranial surgery. These findings indicate that its continued use as the primary surgical approach for most sellar and suprasellar tumors is still favorable even in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.